NCT06361316 Irinotecan Liposome Combined With Oxaliplatin and Tegafur as Adjuvant Therapy for Pancreatic Cancer
| NCT ID | NCT06361316 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Kuirong Jiang |
| Condition | Pancreatic Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 53 participants |
| Start Date | 2024-04-08 |
| Primary Completion | 2025-03-25 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 53 participants in total. It began in 2024-04-08 with a primary completion date of 2025-03-25.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to evaluate the efficacy and safety of irinotecan liposome injection in combined with oxaliplatin plus tegafur (NASOX) for postoperative adjuvant chemotherapy for pancreatic cancer.
Eligibility Criteria
Inclusion Criteria: 1. ECOG performance status 0 or 1. 2. Histologically confirmed resected ductal pancreatic adenocarcinoma with macroscopic complete resection (R0 and R1). 3. ECOG performance status 0 or 1. 4. Life expectancy of greater than or equal to 6 months. 5. Able and willing to provide a written informed consent. Exclusion Criteria: 1. Patients who cannot eat orally and have gastric emptying disorder after surgery; 2. Patients with moderate diarrhea: diarrhea ≥4 times per day; the moderate and severe effluents from stoma increased; Or diarrhea that limits activities of daily living; 3. Patients who cannot eat orally and have gastric emptying disorder after surgery; 4. Patients who cannot eat orally and have gastric emptying disorder after surgery;
Contact & Investigator
KuiRong Jiang, archiater
PRINCIPAL INVESTIGATOR
The First Affiliated Hospital with Nanjing Medical University
Frequently Asked Questions
Who can join the NCT06361316 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Pancreatic Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06361316 currently recruiting?
Yes, NCT06361316 is actively recruiting participants. Contact the research team at Jiangkuirong@163.com for enrollment information.
Where is the NCT06361316 trial being conducted?
This trial is being conducted at Nanjing, China.
Who is sponsoring the NCT06361316 clinical trial?
NCT06361316 is sponsored by Kuirong Jiang. The principal investigator is KuiRong Jiang, archiater at The First Affiliated Hospital with Nanjing Medical University. The trial plans to enroll 53 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.